Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
Pain can negatively affect a person’s quality of life and impede recovery from illness or injury. Recent research compiled by the American Massage Therapy Association (AMTA) suggests that massage can be a helpful pain management strategy for manually controlling symptoms in people suffering metastatic cancer and rheumatoid arthritis, among other illnesses, as well as post-cardiac surgery pain.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61665-amta-massage-therapy-for-pain-relief-cancer-arthritis-post-cardiac-surgery
In recognition of Metastatic Breast Cancer Awareness Day on October 13, AstraZeneca (NYSE: AZN) is raising awareness about the thousands of U.S. women living with metastatic breast cancer. Metastatic Breast Cancer Awareness Day seeks to generate attention and greater support for women living with metastatic breast cancer among the public and stakeholders within the breast cancer community and more research to extend lives.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58129-mbc-awareness
More than 173,000 women in the United States are living with metastatic breast cancer and each has a story to tell. AstraZeneca is launching a nationwide photo-sharing campaign to provide them another way to share their inspiration, experiences and strengths with others.
To show their support, women living with metastatic breast cancer can upload photos of themselves on social media using the campaign hashtag #MBCStrength. Photos posted on Twitter by October 1, 2014 and tagged with #MBCStrength will be considered for a Times Square display in New York City on the fifth anniversary of Metastatic Breast Cancer Awareness Day on October 13, 2014.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7305551-mymbcstory-astrazeneca-encourages-women-with-metastatic-breast-cancer-to-share/
In the U.S., approximately 159,000 women are living with metastatic breast cancer. To raise awareness of Metastatic Breast Cancer Awareness Day on October 13, MedImmune Specialty Care Division of AstraZeneca (NYSE: AZN) is launching the My+Story online resource center, which highlights the needs of women living with metastatic breast cancer and calls attention to metastatic disease as a key component of October’s National Breast Cancer Awareness Month. Metastatic Breast Cancer Awareness Day was officially recognized by the U.S. Congress in 2009, following a grassroots awareness effort led by members of the Metastatic Breast Cancer Network (MBCN).
To view Multimedia News Release, go to http://www.multivu.com/mnr/63080-astrazeneca-metastatic-breast-cancer-awareness
In the United States for 2014, about 62,900 new thyroid cancer cases will be diagnosed. Medullary thyroid cancer – a rare form of cancer located in the thyroid gland at the base of the throat – represents only about three to four percent of all thyroid cancers. Of those cases, just one third will be locally advanced or metastatic disease. With Thyroid Cancer Awareness Month in full swing, AstraZeneca has launched the aMTCSupport.com online resource center to provide information and support specifically designed for people living with advanced medullary thyroid cancer (aMTC) and their loved ones.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7080731-astrazeneca-amtcsupport-resources-for-advanced-medullary-thyroid-cancer/
Today, WebMD released Advanced Breast Cancer: Courage, Comfort and Care with Robin Roberts, a five-part video series developed in partnership with Roberts and her independent production company, Rock’n Robin Productions. The series dives into the daily coping strategies of women living with advanced breast cancer, plus the families and friends who provide encouragement and support, and includes insights from medical experts leading the charge to combat the disease.
Over 255,000 people in the United States will be diagnosed with invasive breast cancer this year, and over 41,000 will die, with metastatic breast cancer being the leading cause of those fatalities. Despite these staggering statistics, there are signs of hope. Treatments for metastatic breast cancer are improving, and they continue to help people with the disease live longer and healthier lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8154851-webmd-advanced-breast-cancer-robin-roberts/
Understanding the burden of metastatic breast cancer (MBC), and the toll it takes on patients and their loved ones, Eisai Inc. announced today the launch of mbcInfoCenter.com, a new online portal designed to provide important resources that may help women with MBC manage their disease and focus on their health and wellness.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7342251-eisai-launches-mbc-infocenter-for-women-with-metastatic-breast-cancer/
